Overview: Fib-4 Score TestIntroduction: The Fib-4 Score Test calculates the Fib-4 score to assess liver fibrosis risk in conditions like hepatitis, helping guide treatment for liver damage or scarring. Affecting 1 in 100 people with liver disease, fibrosis poses diagnostic challenges due to silent progression. Following 2023 American Association for the Study of Liver Diseases (AASLD) guidelines, it uses a calculation based on ALT, AST, and platelets for high utility, supporting biochemistry screening. This test is vital for diagnosis, monitoring, and improving outcomes in hepatology.
Other Names: Fibrosis-4 Index Test, Liver Fibrosis Score Assay.
FDA Status: Non-invasive calculation, meeting biochemistry standards for diagnostic reliability.
Historical Milestone: Fib-4 scoring began in the 2000s with research by Sterling, who developed the formula. Validation studies in the 2010s by NIH improved its use, surpassing earlier biopsy methods.
Purpose: Calculates Fib-4 score to assess fibrosis risk, guides antiviral therapy or monitoring, and evaluates patients with liver disease, aiming to prevent cirrhosis.
Test Parameters: Fib-4 score
Pretest Condition: No special preparation required. Collect serum. Report history of liver disease.
Specimen: Serum (SST, 2-5 mL); 2 mL serum in SST. Transport in a biohazard container.
Sample Stability at Room Temperature: 6 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document liver disease history or jaundice. Include current medications or alcohol use.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., cirrhosis), and sample collection risks.
Procedural Considerations: Uses calculation (ALT, AST, platelets) to derive Fib-4 score, requiring labs with analyzers. Results available in 1-2 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample hemolysis or inaccurate platelet counts can skew results. Medications may alter liver enzymes, requiring correlation.
Clinical Significance: High score indicates fibrosis, guiding therapy. Early intervention might prevent progression, while untreated cases lead to cirrhosis. Low scores may require imaging.
Specialist Consultation: Consult a hepatologist for interpretation.
Additional Supporting Tests: FibroScan, liver biopsy, or viral load to confirm diagnosis.
Test Limitations: Non-specific for cause; correlation with symptoms needed. Requires accurate lab data.
References: AASLD Guidelines, 2023; Hepatology, Sterling RK, 2022.
